183 related articles for article (PubMed ID: 3718102)
1. Bromocriptine reduces growth hormone in acromegaly.
Bell PM; Atkinson AB; Hadden DR; Kennedy L; Leslie H; Merrett JD; Sheridan B
Arch Intern Med; 1986 Jun; 146(6):1145-9. PubMed ID: 3718102
[TBL] [Abstract][Full Text] [Related]
2. Effect of long term bromocriptine treatment on glucose intolerance in acromegaly.
Chiba T; Chihara K; Minamitani N; Goto B; Kadowaki S; Taminato T; Matsukura S; Fujita T
Horm Metab Res; 1982 Feb; 14(2):57-61. PubMed ID: 7040191
[TBL] [Abstract][Full Text] [Related]
3. Experiences with bromocriptine treatment in acromegaly--a preliminary report.
Nilsson A
Acta Endocrinol Suppl (Copenh); 1978; 216():217-24. PubMed ID: 274038
[TBL] [Abstract][Full Text] [Related]
4. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
[TBL] [Abstract][Full Text] [Related]
5. [Normalization of the GH response to L-DOPA in acromegalics after treatment with bromocriptine].
Carmina E; Lanzara P; Lo Coco R; Longo RA; Jannì A
Arch Sci Med (Torino); 1979; 136(3):421-5. PubMed ID: 549547
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of acromegaly using bromocriptine].
Köbberling J; Schwinn G; Dirks H
Dtsch Med Wochenschr; 1975 Jul; 100(29):1540-2. PubMed ID: 1149634
[TBL] [Abstract][Full Text] [Related]
7. Bromocriptine therapy in eleven patients with acromegaly.
Lundin L; Ljunghall S; Wide L; Boström H
Acta Endocrinol Suppl (Copenh); 1978; 216():207-16. PubMed ID: 347863
[TBL] [Abstract][Full Text] [Related]
8. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
9. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
[TBL] [Abstract][Full Text] [Related]
10. Bromocriptine and glucose tolerance in acromegalics.
Dolecek R; Kubis M; Sajnar J; Závada M
Pharmatherapeutica; 1982; 3(2):100-6. PubMed ID: 7048336
[TBL] [Abstract][Full Text] [Related]
11. Homocysteine levels in acromegaly patients.
Hekimsoy Z; Ozmen B; Ulusoy S
Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of bromocriptine treatment for acromegaly.
Maneschi F
Horm Res; 1980; 12(4):191-205. PubMed ID: 7390405
[TBL] [Abstract][Full Text] [Related]
13. Medical management of acromegaly with bromocriptine. Effects of continuous treatment for over three years.
Besser GM; Wass JA
Med J Aust; 1978 Nov; 2(3 Suppl):31-3. PubMed ID: 745579
[TBL] [Abstract][Full Text] [Related]
14. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
Fredstorp L; Kutz K; Werner S
Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
[TBL] [Abstract][Full Text] [Related]
15. Bromocriptine therapy in patients with acromegaly: effects on growth hormone, somatomedin A and prolactin.
Werner S; Hall K; Sjöberg HE
Acta Endocrinol Suppl (Copenh); 1978; 216():199-206. PubMed ID: 347862
[TBL] [Abstract][Full Text] [Related]
16. Response of acromegaly to long term bromocriptine therapy: a biochemical and clinical assessment.
Clayton RN; Vrionides Y; Lynch SS; Butt WR; London DR
Acta Endocrinol (Copenh); 1978 Nov; 89(3):469-82. PubMed ID: 360752
[TBL] [Abstract][Full Text] [Related]
17. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.
Dobrashian RD; O'Halloran DJ; Hunt A; Beardwell CG; Shalet SM
Clin Endocrinol (Oxf); 1993 Jun; 38(6):589-93. PubMed ID: 8334745
[TBL] [Abstract][Full Text] [Related]
18. Plasma growth hormone suppressive effect of bromocriptine in acromegaly. Evaluation by plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests.
Nortier JW; Croughs RJ; Thijssen JH; Schwarz F
Clin Endocrinol (Oxf); 1984 May; 20(5):565-71. PubMed ID: 6744634
[TBL] [Abstract][Full Text] [Related]
19. Acromegaly--results of long term treatment with bromocriptine.
Besser GM; Wass JA; Thorner MO
Acta Endocrinol Suppl (Copenh); 1978; 216():187-98. PubMed ID: 347861
[TBL] [Abstract][Full Text] [Related]
20. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
